SCHEMBL8235484

SCHEMBL8235484

CC(C)(O)c1cccc(-c2ccn3nc(-c4ccc(Cl)cc4)cc3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.56
KCNH2 Q12809 1/20 0.56
MAP4K4 O95819 1/20 0.39
CYP17A1 P05093 1/20 0.38
CYP3A4 P08684 1/20 0.38
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
PGR P06401 1/20 0.35
MAPT P10636 4/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
LMNA P02545 2/20 0.34
STAT3 P40763 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8228449 0.88 NR4A2 (0.42) NR4A2KCNH2CYP17A1CYP3A4PGR
SCHEMBL8228445 0.79 NR4A2 (0.56) NR4A2SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL8236368 0.78 CYP2C9 (0.54) NR4A2KCNH2SMN1; SMN2MEN1KMT2A
SCHEMBL8236173 0.78 SMN1; SMN2 (0.38) NR1H2NR1H3SMN1; SMN2MEN1KMT2A
SCHEMBL10475891 0.77 CYP17A1 (0.35) NR4A2KCNH2CYP17A1CYP3A4KDM4E
SCHEMBL2027826 0.76 NR4A2 (0.56) NR4A2MAP4K4RXRARXRBTDP2
SCHEMBL12543372 0.76 GABRG2 (0.49) NR4A2MEN1KMT2ANPC1RAB9A
SCHEMBL2032150 0.76 NR4A2 (0.58) NR4A2MEN1KMT2ATDP2
SCHEMBL2032771 0.76 ERN1 (0.43) NR4A2TDP2CTRC
SCHEMBL8233686 0.76 TRIM24 (0.42) SMN1; SMN2MEN1KMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477990-B1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-20 EP claimed
US-8618301-B2 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof SANOFI (FR) 2013-12-31 US claimed
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-24 US claimed
EP-2477990-B1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-20 EP disclosed
US-8618301-B2 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof SANOFI (FR) 2013-12-31 US disclosed
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-24 US disclosed
EP-2477990-A1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-07-25 EP disclosed
WO-2011033230-A1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023554-A1 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF CBR3, CBR1, OGFR NR4A2 296/4885KCNH2 64/4885MAP4K4 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.